Protein S100B as a reliable tool for early prognostication after cardiac arrest.


Journal

Resuscitation
ISSN: 1873-1570
Titre abrégé: Resuscitation
Pays: Ireland
ID NLM: 0332173

Informations de publication

Date de publication:
11 2020
Historique:
received: 09 04 2020
revised: 15 07 2020
accepted: 08 08 2020
pubmed: 29 8 2020
medline: 22 6 2021
entrez: 29 8 2020
Statut: ppublish

Résumé

Early and reliable prognostication after cardiac arrest (CA) remains crucial. We hypothesized that protein-S100B (PS100B) could predict more accurately outcome in the early phase of CA compared with other current biomarkers. This prospective single-center study included 330 adult comatose non-traumatic successfully resuscitated CA patients, treated with targeted temperature management but not extra-corporeal life support. Lactate, pH, creatinine, NSE, and PS100B were sampled in ICU early after return of spontaneous circulation (ROSC) corresponding to admission (Adm). Serial measurements were also performed at H24 and H48. PS100B was the sole biomarker blinded to physicians. The median delay between ROSC and first PS100B sampling was 220 min. At admission, all biomarkers were significantly associated with good outcome (CPC1-2; 109 patients) at 3-month follow-up (P ≤ 0.001, except for NSE: P = 0.03). PS100B-Adm showed the best AUC of ROC curves for outcome prediction at 3-month (AUC 0.83 [95%-CI: 0.78-0.88]), compared with other biomarkers (P < 0.0001), while AUC for lactate-Adm was higher than for NSE-Adm. AUC for PS100B-H24 was significantly higher than for other biomarkers except NSE-H24 (P ≤ 0.0001), while AUC for NSE-H24 was higher than for lactate-H24 and pH-H24. AUCs for PS100-H48 and NSE-H48 were significantly higher than for all other biomarkers (P < 0.001). Compared to patients with decreased PS100B values over time, an increasing PS100B value between admission and H24 was significantly associated with poor outcome at 3 months (P = 0.001). No-flow, initial non-shockable rhythm, PS100B-Adm, lactate-Adm, pH-Adm, clinical seizures, and absence of therapeutic hypothermia were independent predictors associated with poor outcome at 3-month in multivariate analysis. Net-Reclassification-Index was 70%, 64%, and 81% when PS100B-Adm was added to the clinical model, to clinical model with NSE-Adm, and to clinical model with standard biological parameters, respectively. Early PS100B compared with other biomarkers was independently correlated with outcome after CA, with an interesting added value.

Identifiants

pubmed: 32858156
pii: S0300-9572(20)30321-X
doi: 10.1016/j.resuscitation.2020.08.010
pii:
doi:

Substances chimiques

Biomarkers 0
S100 Calcium Binding Protein beta Subunit 0
S100B protein, human 0
Phosphopyruvate Hydratase EC 4.2.1.11

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

251-259

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Nicolas Deye (N)

Medical ICU, Lariboisiere University Hospital, APHP, Paris, France; Inserm UMR-S 942, Lariboisiere Hospital, Paris, France. Electronic address: n.deye@orange.fr.

Philippe Nguyen (P)

Medical ICU, Lariboisiere University Hospital, APHP, Paris, France.

Nicolas Vodovar (N)

Inserm UMR-S 942, Lariboisiere Hospital, Paris, France.

Malha Sadoune (M)

Inserm UMR-S 942, Lariboisiere Hospital, Paris, France.

Corinne Collet (C)

Inserm UMR-S 942, Lariboisiere Hospital, Paris, France; Biochemical Laboratory, Lariboisiere University Hospital, APHP, Paris, France.

Sebastian Voicu (S)

Medical ICU, Lariboisiere University Hospital, APHP, Paris, France.

Isabelle Malissin (I)

Medical ICU, Lariboisiere University Hospital, APHP, Paris, France.

Etienne Gayat (E)

Inserm UMR-S 942, Lariboisiere Hospital, Paris, France; Surgical ICU, Lariboisiere University Hospital, Paris, France.

Jeanne-Lise Samuel (JL)

Inserm UMR-S 942, Lariboisiere Hospital, Paris, France.

Claude Delcayre (C)

Inserm UMR-S 942, Lariboisiere Hospital, Paris, France.

Jean-Marie Launay (JM)

Inserm UMR-S 942, Lariboisiere Hospital, Paris, France; Biochemical Laboratory, Lariboisiere University Hospital, APHP, Paris, France.

Alain Cohen-Solal (A)

Inserm UMR-S 942, Lariboisiere Hospital, Paris, France; Cardiology Department, Lariboisiere University Hospital, Paris, France.

Bruno Mégarbane (B)

Medical ICU, Lariboisiere University Hospital, APHP, Paris, France; Inserm U 1140, Lariboisiere Hospital, Paris, France.

Alexandre Mebazaa (A)

Inserm UMR-S 942, Lariboisiere Hospital, Paris, France; Surgical ICU, Lariboisiere University Hospital, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH